GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (NAS:BIOL) » Definitions » Median PS Value

Biolase (Biolase) Median PS Value : $60.68 (As of Apr. 28, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Biolase Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Biolase's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $71.337. Biolase's 10-Year median PS Ratio is 0.8506. Therefore, the Median PS Value for today is $60.68.

As of today (2024-04-28), Biolase's share price is $0.148. Biolase's Median PS Value is $60.68. Therefore, Biolase's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Biolase's Median PS Value or its related term are showing as below:

During the past 13 years, the highest Price to Median PS Value of Biolase was 1.39. The lowest was 0.02. And the median was 0.57.

BIOL's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.78
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Biolase Median PS Value Historical Data

The historical data trend for Biolase's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase Median PS Value Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,232.83 1,225.16 827.50 765.99 60.68

Biolase Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 765.99 588.89 387.91 230.52 60.68

Competitive Comparison of Biolase's Median PS Value

For the Medical Devices subindustry, Biolase's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biolase's Price-to-Median-PS-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Biolase's Price-to-Median-PS-Value falls into.



Biolase Median PS Value Calculation

Biolase's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=71.337*0.8506
=60.68

10-Year Median PS Ratio is 0.8506.
Biolase's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $71.337.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biolase  (NAS:BIOL) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Biolase's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.148/60.68
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biolase Median PS Value Related Terms

Thank you for viewing the detailed overview of Biolase's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolase (Biolase) Business Description

Traded in Other Exchanges
Address
27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
Executives
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Lord Jonathan T Md director 500 WEST MAIN ST., LOUISVILLE KY 40202
Jennifer Bright officer: Chief Financial Officer 27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Steven Sandor officer: Chief Operating Officer 27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Jess Roper director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Kenneth P. Yale director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
John R Beaver director, officer: President & CEO C/O STERLING CHEMICALS INC, 1200 SMITH STREET, HOUSTON TX 77002
Kathleen T Oloughlin director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Somerman Martha J. Dds, Phd director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Summerhays Carol Gomez Dds director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Family Foundation Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Larry N Feinberg 10 percent owner C/O ORACLE PARTNERS L P, 200 GREENWICH AVENUE, GREENWICH CT 06830
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Michael Ditolla director 3299 CAMBRIDGE AVE, BRONX NY 10463